{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:08:23Z","timestamp":1783822103706,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40261-026-01572-w","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:36:03Z","timestamp":1781274963000},"page":"803-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amyloid-Related Imaging Abnormalities in Anti-amyloid Therapy: Clinical Implications of Kinetics for Safer Use and Risk Stratification"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-025X","authenticated-orcid":false,"given":"Ozlem","family":"Totuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"2","key":"1572_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16049","volume":"31","author":"R Perneczky","year":"2024","unstructured":"Perneczky R, Dom G, Chan A, Falkai P, Bassetti C. Anti-amyloid antibody treatments for Alzheimer\u2019s disease. Eur J Neurol. 2024;31(2):e16049. https:\/\/doi.org\/10.1111\/ene.16049.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1572_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s40001-023-01512-w","volume":"28","author":"W Wu","year":"2023","unstructured":"Wu W, Ji Y, Wang Z, et al. The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res. 2023;28(1):544. https:\/\/doi.org\/10.1186\/s40001-023-01512-w.","journal-title":"Eur J Med Res"},{"issue":"1","key":"1572_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"6","key":"1572_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"issue":"11","key":"1572_CR5","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146(11):4414\u201324. https:\/\/doi.org\/10.1093\/brain\/awad188.","journal-title":"Brain"},{"key":"1572_CR6","doi-asserted-by":"publisher","first-page":"1326784","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784. https:\/\/doi.org\/10.3389\/fnins.2024.1326784.","journal-title":"Front Neurosci"},{"issue":"12","key":"1572_CR7","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/psp4.13224","volume":"13","author":"O Majid","year":"2024","unstructured":"Majid O, Cao Y, Willis BA, et al. Population pharmacokinetics and exposure\u2013response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer\u2019s disease. CPT Pharmacomet Syst Pharmacol. 2024;13(12):2111\u201323. https:\/\/doi.org\/10.1002\/psp4.13224.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"1572_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamaneurol.2024.3937","volume":"82","author":"S Salloway","year":"2025","unstructured":"Salloway S, Wojtowicz J, Voyle N, et al. Amyloid-related imaging abnormalities (ARIA) in clinical trials of gantenerumab in early Alzheimer disease. JAMA Neurol. 2025;82(1):19\u201329. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3937.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1572_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae435","volume":"6","author":"M Aljuhani","year":"2024","unstructured":"Aljuhani M, Ashraf A, Edison P. Evaluating clinical meaningfulness of anti-\u03b2-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer\u2019s disease. Brain Commun. 2024;6(6):fcae435. https:\/\/doi.org\/10.1093\/braincomms\/fcae435.","journal-title":"Brain Communications"},{"issue":"9","key":"1572_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/jpm15090437","volume":"15","author":"AE Alkhalifa","year":"2025","unstructured":"Alkhalifa AE, Al Mokhlf A, Ali H, Al-Ghraiybah NF, Syropoulou V. Anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: evidence, ARIA risk, and precision patient selection. J Pers Med. 2025;15(9):437. https:\/\/doi.org\/10.3390\/jpm15090437.","journal-title":"J Pers Med."},{"issue":"5","key":"1572_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","volume":"82","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA, Ardayfio P, Wang H, et al. Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol. 2025;82(5):461\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0065.","journal-title":"JAMA Neurol"},{"key":"1572_CR12","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1192\/bjo.2025.10235","volume":"11","author":"SS Rajan","year":"2025","unstructured":"Rajan SS, Babhulkar S, Uppal G, Bhattacharyya S, Dhandapani AD. Comparative safety profiles of anti-amyloid therapies in early Alzheimer\u2019s disease (AD): a detailed systematic review and meta-regression analysis of amyloid related imaging abnormalities (ARIA): incidence and infusion reactions for lecanemab, donanemab, and aducanumab. BJPsych Open. 2025;11:S71\u20132. https:\/\/doi.org\/10.1192\/bjo.2025.10235.","journal-title":"BJPsych Open"},{"issue":"8","key":"1572_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100266","volume":"12","author":"H Wang","year":"2025","unstructured":"Wang H, Nery ESM, Ardayfio P, et al. The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. The Journal of Prevention of Alzheimer\u2019s Disease. 2025;12(8), 100266. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100266.","journal-title":"The Journal of Prevention of Alzheimer's Disease"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01572-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01572-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01572-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:02:32Z","timestamp":1783821752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01572-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01572-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No financial support was received for the conduct, preparation, or publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ozlem Totuk has no conflicts of interest that are direclty relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is a Current Opinion based exclusively on previously published literature and does not involve any new studies with human participants or animals performed by the author. Therefore, ethics committee approval was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data cited in this article are publicly available in the referenced literature.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"OT is the sole author of this article and takes full responsibility for its integrity and content. The author conceptualized the manuscript, performed the literature review, drafted and revised the manuscript, and approved the final version for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"AI-assisted tools (e.g., ChatGPT) were used solely to enhance grammar, clarity, and style. The author assumes full responsibility for the accuracy and interpretation of the content.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI Tools"}}]}}